SCHEMBL3979341

SCHEMBL3979341

CCNC(c1ncccc1CN(Cc1cc(C(F)(F)F)cc(C(F)(F)F)c1)c1nnn(C)n1)C1CCCC1

nearest known ligand 0.39

Predicted protein targets (top 1)

geneUniProtsupporting neighboursconfidence
CETP P11597 20/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4223079 0.88 CETP (0.38) CETP
SCHEMBL3979337 0.87 CETP (0.39) CETP
SCHEMBL3910899 0.85 CETP (0.38) CETP
SCHEMBL27743969 0.84 CETP (0.41) CETP
SCHEMBL3910894 0.80 CETP (0.38) CETP
SCHEMBL1600913 0.76 CETP (0.47) CETP
SCHEMBL1600443 0.76 CETP (0.46) CETP
SCHEMBL1600442 0.76 CETP (0.46) CETP
SCHEMBL4220329 0.76 CETP (0.39) CETP
SCHEMBL3578647 0.75 CETP (0.37) CETP

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2018376-A1 BENZYLAMINE DERIVATIVES AS CETP INHIBITORS Novartis Pharma AG (CH) 2009-01-28 EP disclosed
WO-2007132906-A1 BENZYLAMINE DERIVATIVES AS CETP INHIBITORS NOVARTIS AG (CH) 2007-11-22 WO disclosed